



Corporate Fact Sheet



Founded
1973

Funds under management
over \$1.25 billion

No of employees
31

Expertise includes
scientific, business, clinical,
financial, legal, investment
banking, fund-raising,
operating and recruiting

We invest in
the US, Europe and Asia

We invest across
seed, start-up, development,
pre-IPO, public and growth
equity in life sciences and
healthcare

Our approach
long-term, supportive and
knowledgeable

Offices in the UK
London
+ 44 (0)20 7534 1500

Offices in the US
Waltham, Massachusetts
+ 781 466 8800

Menlo Park, California
+ 650 926 0600

Website
www.abingworth.com

Last updated
January 2010



Abingworth is an international investment group dedicated to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.

Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Our specialist team of over 20 professionals has a broad range of skills that are made available to portfolio companies. Abingworth has funds under management of over \$1.25 billion and offices in London, Menlo Park, CA, and Boston, MA.

Dedicated to life sciences and healthcare

Abingworth seeks to identify and invest in the best opportunities in the life sciences and healthcare markets. Our investments and expertise are balanced across all stages of company development including venture capital, growth equity and public companies.

| | |
|--------------------|--|
| Sector | Life Sciences and Healthcare |
| Size of Investment | \$20-\$80 million* |
| Investment Stage | Early and late-stage venture, growth equity and public markets |
| Ownership | Minority and majority |
| Geography | Primarily the US, UK and Europe |

**Monies may be invested over more than one round of financing*

Investments have been made in platform and enabling technologies, medical devices, instrumentation and in companies developing therapeutics. We have also invested in spin-outs and maturing companies with revenues and profits.

Abingworth's team has significant scientific and business expertise as well as investment banking, recruitment and legal knowledge. Our resources are complimented by a network of leading scientific and industry consultants who contribute to the process of evaluating new opportunities, creating companies and supporting existing portfolio investments.

Abingworth's approach

Abingworth seeks long-term involvement with its investments and provides much more than financial backing. Our objective is to be supportive and help identify solutions. The company takes an open and active role in guiding the development of portfolio companies.

Funds

Abingworth has raised nine funds dedicated to investment in life sciences and healthcare: **Abingworth Bioventures V** expanded to £392 million with the addition of £84 million raised in December 2008. The new monies were raised in an affiliated fund, **Abingworth Bioventures V Co-Invest Growth Equity Fund**. These funds are actively investing. **Abingworth BioEquities** is an open-ended fund and Abingworth's first fund dedicated solely to investments in quoted stocks.

Previous funds are either fully liquidated or making no new investments.

Portfolios can be viewed on the Abingworth website: www.abingworth.com

Investment success

Portfolio companies have included Ablynx, Alnylam Pharmaceuticals, Aurora Biosciences, Aviron, GelTex Pharmaceuticals, Gilead Sciences, Healtheon, IDEC Pharmaceuticals, Neurocrine Biosciences, Pharmion, PowderMed and Solexa (now part of Illumina).

The Abingworth Team



In the UK



Stephen Bunting, Managing Partner has more than 25 years experience of life science venture capital investment. He

joined Abingworth in 1987 and became its Managing Director in 2002. He has been a Director of a number of companies in the US and Europe and was Founding Chairman of Astex Therapeutics, Devgen and Hexagen. Other directorships have included Ablynx, Aurora Biosciences and Genetic Therapy.

James Abell, Partner and CFO

handles Abingworth's finance and administration as well as investment matters, focusing on start-up companies where he offers substantial operational support. His directorships have included Chroma Therapeutics, Clinical Designs and Syntaxin.

Joseph Anderson, Partner leads private investments in public companies in the US and Europe and manages open market portfolios of small-cap public equities. He is a director of Algeta and Amarin Corporation.

Tim Haines, Partner identifies and creates new businesses and provides support for portfolio companies. His current and past board positions include Astex Therapeutics, Fovea, Healthcare Brands International, Intelligent Medical Implants, PowderMed, Stanmore Implants and XCounter.

David Leathers, Partner has primary responsibility for Abingworth's investor relations in the US and Europe. His directorships have included GeneMedicine, GenPharm International and Pharming.

Genghis Lloyd-Harris, Partner focuses on exits of Abingworth's venture investments via mergers and acquisitions and IPOs as well as venture investment in the UK and Continental Europe. His directorships have included Healthcare Brands International, Novoxel, Solexa and Synosia Therapeutics.

Andy Sandham, Venture Partner helps to identify and create new businesses and provides strategic and operational support for portfolio companies. His current board positions include NeurAxon, Novacta, Syntaxin and PBL Technology.

Alex Asquith, Assistant Counsel assists Abingworth's General Counsel and CFO and provides legal support to the life sciences and healthcare team.

John Heard, General Counsel is responsible for deal co-ordination and provides legal assistance to the life sciences and healthcare team.

Sarah Shackelton, Principal, Marketing and Management Teams expands Abingworth's relationships with key industry executives and entrepreneurs and assists portfolio companies with their recruitment needs.

John Shields, Principal, Science and Technology is involved with scientific evaluation of new and existing investments and works closely with UK universities and early-stage companies.

Andrew Sinclair, Portfolio Manager evaluates investment opportunities in public companies and is a fund manager for open market transactions.

Victoria Stewart, Principal, Public Relations manages and advises on Abingworth's public relations strategy in Europe and the US.

East Coast US



Michael F. Bigham, Partner has 14 years of operational experience and six years investment banking experience in

life science companies. He joined Abingworth in 2002. Michael's current directorships include Avila Therapeutics, Magellan, Supernus Pharmaceuticals and Valeritas. He is responsible for Abingworth's Boston office.


David Mayer, Partner focuses on Abingworth's investments in growth equity. These include growth capital and acquisition financings, growth buyouts and build-ups in healthcare services and life sciences companies.

Vincent Miles, Venture Partner is involved with technical and scientific evaluation of investments, focusing on East Coast deals. He is a director of Hydra Biosciences and PrimeraDx.

Michelle Doig, Principal, Corporate Finance advises on funding and re-financing of portfolio companies and expanding relationships within the VC community.

Reed Van Gorden, Associate assists in evaluation of growth equity investments.

West Coast US



Jonathan MacQuitty, Partner has more than 15 years of operational experience in life science companies and

12 years of venture capital experience. His directorships have included Adiana, Dicerna, Entelos, Gynesonics, Labcyte, ParAllele BioScience and Sunesis Pharmaceuticals. Jonathan is responsible for Abingworth's Menlo Park office.

Ken Haas, Venture Partner helps to identify and create new businesses, focusing on West Coast deals. His directorships include Broncus Technologies, Gynesonics, Intellikine, Pathwork Diagnostics and Zogenix.